<DOC>
	<DOC>NCT01607918</DOC>
	<brief_summary>The investigators aimed to compare the eradication rates of sequential therapy for 10 days versus triple therapy for 14 days</brief_summary>
	<brief_title>Clarithromycin-based Triple Therapy for 14 Days Versus Sequential Therapy 10 Days in the First Line Therapy</brief_title>
	<detailed_description />
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<criteria>Patients are aged greater than 20 years who have H. pylori infection without prior eradication therapy and are willing to receive the sequential therapy will be eligible for enrollment. Written informed consents will be obtained from all patients prior to enrollment. Patients will be excluded from the study if any one of the following criteria is present: children and teenagers aged less than 20 years, history of gastrectomy, gastric malignancy, including adenocarcinoma and lymphoma, previous allergic reaction to antibiotics (amoxicillin, clarithromycin, levofloxacin, metronidazole) and prompt pump inhibitors (lansoprazole), contraindication to treatment drugs, pregnant or lactating women, severe concurrent disease Patients who cannot give informed consent by himself or herself.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>H pylori, eradication</keyword>
</DOC>